Accelerated rotational-field deep TMS for obsessive-compulsive disorder

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind trial comparing active rotational-field Deep TMS targeting the medial prefrontal cortex and anterior cingulate with a sham coil over 13 weeks. Participants are randomized 1:1 and receive a total of 39 sessions following an accelerated protocol that includes an initial five-day acute phase of three daily sessions, a five-week maintenance phase with once-weekly sessions, and follow-up visits at weeks 8, 10, and 13. Each daily treatment day during the acute phase consists of three sessions separated by one-hour intervals, and imaging is obtained at baseline and after the maintenance phase. The trial uses BrainsWay H-coils for active stimulation and matched sham coils for blinding.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Outpatients
* Diagnosed as suffering from OCD according to the DSM-V.
* Subjects with a YBOCS score of \>20.
* If on SRI, patient must be maintained on current dosages (with or without additional antidepressant or psychotropic augmentation for treatment of OCD), at a stable therapeutic dosage for at least 2 months prior to study entry and for the duration of the trial.
* If in CBT, must be in the maintenance stage (i.e., not receiving active training in exposure and response prevention, which is the core component of this treatment). CBT can be with teletherapy but must be for a minimum of ten sessions with a symptom checklist, hierarchy, with exposure and response prevention therapy.
* Have negative or justified responses by the investigator to all questions listed on the Transcranial Magnetic Stimulation Safety Screening questionnaire (TASS).
* According to the treating physician the subject is compliant with taking medication, if applicable.
* Subject is capable and willing to provide informed consent and assent.
* Willing and able to adhere to the treatment schedule.
* All comorbid diagnoses have been stable for 3 months and anticipated to be stable for the 3 months treatment duration.

Exclusion Criteria:

* Subjects diagnosed as suffering from any other Axis I diagnosis as the primary diagnosis.
* Comorbid, secondary psychiatric diagnoses are unstable and are likely to require changes in therapeutic regimens even if OCD improves.
* Present suicidal risk as assessed by the investigator using the Columbia Suicide Severity Rating Scale, brief mental status exam and psychiatric interview or a history of attempted suicide in the past year.
* History of epilepsy or seizure (EXCEPT those therapeutically induced by ECT and febrile seizures in infancy).
* Increased risk of seizure for any reason, including prior diagnosis of increased intracranial pressure, or history of significant head trauma with loss of consciousness for greater than or equal to 5 minutes.
* History of head injury necessitating cranial surgery or prolonged coma.
* History of any ferromagnetic of conductive material in the head including the eyes and ears (outside the mouth).
* Known history of any metallic particles in the eye, implanted neurostimulators, intracranial implant (e.g., aneurysm clips, shunts, stimulators, cochlear implants, or electrodes).
* History of significant hearing loss.
* Subjects with significant neurological disorder or insult
* Substance use disorder within the past 6 months (except nicotine and caffeine and based on the doctor's judgment).
* Currently participating in another therapeutic clinical study.
* Suffer from an unstable physical, systemic and metabolic disorder such as unstable blood pressure, unstable blood sugar, or acute, unstable cardiac disease.
* Subject on high doses of antidepressant or psychotropic medications, which are known to lower the seizure threshold. Subject is currently on Clomipramine.
* Significant possibility of death within eighteen months of baseline.
* Planned surgeries that will interrupt the study schedule within four months of baseline.
* Women who are breast-feeding.
* Women who are pregnant or with suspected pregnancy.
* Women of childbearing potential and not using a medically accepted form of contraception when engaging in sexual intercourse.

Where it's running

• Soroka University Medical Center
  Beersheba, Israel Recruiting

Study contacts

• Principal investigator: Abraham Zangen, Prof. — Ben-Gurion University of the Negev
• Study coordinator: Dor Shukrun, PhD Student
• Email: dor.yshukrun@gmail.com
• Phone: +972547551542

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Low-intensity focused ultrasound targeting the subthalamic nucleus for OCD

  A short test is being done to see if a wearable, non-invasive ultrasound device can safely and tolerably help adults with OCD by targeting a brain region called the subthalamic nucleus.

  Recruiting Phase 2 University of Pennsylvania · Philadelphia, Pennsylvania · NCT07887633

• Mindfulness-Based Cognitive Therapy for OCD Delivered Online

  This study tests a synchronous online MBCT program for adults with OCD to see if it is acceptable and feasible and to explore links between biological markers, OCD severity, and treatment response.

  Recruiting IRCCS Centro San Giovanni di Dio Fatebenefratelli · Brescia · NCT07834567

• Targeted brain stimulation for OCD: test of tTIS on nucleus accumbens

  This study tests whether targeted temporal interference stimulation of the nucleus accumbens can help reduce obsessive-compulsive symptoms in adults with OCD, compared with sham stimulation.

  Recruiting Beijing HuiLongGuan Hospital · Hefei, Anhui · NCT07805200

• Anxiety Skills Study: See if video skill training plus therapy helps people with anxiety

  This study tests whether a brief video-based skill training can help people with anxiety as well as four therapy sessions, and how durable the effects are over a year.

  Recruiting Ohio State University · Columbus, Ohio · NCT07774481

• AttunE LIFU for OCD: a non-invasive brain stimulation study

  This trial tests ATTN201, a wearable ultrasound headband, to see if it helps adults with OCD compared to a sham treatment.

  Recruiting Phase 2 University of Pennsylvania · San Francisco, California · NCT07728994

• Combined ERP and Habit Reversal Therapy for Tourettic OCD

  This study tests whether a merged Exposure and Response Prevention and Habit Reversal Therapy helps adults with Tourettic OCD more than either therapy alone or basic psychoeducation.

  Recruiting at 2 sites University College London Hospitals · London, London and 1 other locations · NCT07725926

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.